Carolin Barth, MD
Carolin Barth brings over 15 years of global pharmaceutical industry experience across commercialization and development. Prior to joining MiroBio, she served as global head of commercial and pipeline strategy, cell and gene, at Novartis Oncology. Before that, Carolin held roles of increasing responsibility at Novartis, serving as global head for several development programs and as a commercial launch leader in the areas of dermatology, rheumatology and chronic myeloid leukemia. She played an instrumental role in the development and commercialization of antibody therapies, including COSENTYX® and XOLAIR®. Carolin began her corporate career at McKinsey & Company. She holds an MD from the University of Tübingen, Germany, where she also completed her medical residency.